Skip to main content

Lung Cancer Diagnostics Market Size [2022-2028] | Industry Size, Share, Growth & Forecast Analysis

Written by Customer Service on . Posted in Mergers And Acquisitions.

Key Players Covered in Lung Cancer Diagnostics Market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, AstraZeneca plc, Illumina Inc., Agilent Technologies, Inc. Qiagen.

Pune, India, March 13, 2022 (GLOBE NEWSWIRE) — The global lung cancer diagnostics market size is projected to experience dynamic expansion in the upcoming years owing to the increasing prevalence of smoking, finds Fortune Business Insights™ in its report, titled “Lung Cancer Diagnostics Market, 2021-2028”.

Industry Development:

June 2019: First in vitro diagnostic immunohistochemistry (IHC) assay was launched by Roche Diagnostics with an aim to offer improved detection of lung cancer.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/lung-cancer-diagnostics-market-102003


Market Growth Drivers:

In recent years, there has been an increasing awareness about lung cancer among the world population due to the emergence of advanced technologies in healthcare industry and the wide availability of internet and data across the world. Thus, this is a major factor driving the growth of this market.

  • Introduction of Technologically Advanced Systems to Propel Lung Cancer Diagnostics Market Growth
  • Extensive Distribution Network, Strong Portfolio, and Stout Brand Presence to Boost the Market
  • Rapid Shift towards Latest Technology in Developed and Emerging Countries
  • Launch of Innovative and Advanced Products is Propelling the Growth of the Market
  • Clinical Efficiency of New Products to Boost its Adoption during 2021-2028
  • Higher Demand in COVID-19 Pandemic to Propel Market Growth
  • Product Innovations and Regional Expansions to Augment Market Growth
  • Growing Research & Development Investments and Increasing New Product approvals to Drive Market Growth
  • Robust Product Offerings by Key Players to Propel Industry Growth
  • Strategic Partnerships Coupled with Strong Brand Presence to Foster Company Growth


Click here to get the short-term and long-term impact of COVID-19 on this market.

Please Visit: https://www.fortunebusinessinsights.com/lung-cancer-diagnostics-market-102003


Market Segments:

  • On the basis of cancer type, this market is categorized into Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
  • Based on test, the market is divided into imaging tests, sputum cytology, biopsy, molecular tests, and other tests.
  • By end-user, the Lung Cancer Diagnostics Market is classified into hospitals, specialty clinics, and others.
  • Based on geography, the market is clubbed into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Regional Analysis:

North America region is anticipated to witness substantial growth in the lung cancer diagnostics market share on account of the increasing technological advancements in lung cancer treatment and the increasing prevalence of smoking in this region.

Asia Pacific region is projected to grow at a decent pace in this market owing to the improvement in the research and development of diagnostic tools in this region.


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/queries/lung-cancer-diagnostics-market-102003


Competitive Landscape:

The prominent companies in the lung cancer diagnostics market are focusing on the introduction of advanced devices for lung cancer treatment and early diagnosis in order to reduce the adverse impact of lung cancer. This has resulted in the increasing competition among key companies which will enable them to widen their business horizons and strengthen their market position.

List of key players:

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific
  • AstraZeneca plc
  • Illumina Inc.
  • Agilent Technologies, Inc.
  • Qiagen


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.